Following primary infection Epstein-Barr virus (EBV) establishes a persistent infection which is
Introduction
Epstein-Barr virus (EBV) is a lymphotropic herpesvirus which, on infection in vitro, immortalizes human B cells to yield continuously proliferating lymphoblastoid cell lines (LCL) (Pope et al., 1968) . The majority of the human population undergo subclinical infection with EBV during childhood (Niederman et al., 1970) , and the virus then establishes a lifelong persistent infection in two cellular sites -squamous epithelial cells and B lymphocytes (Sixbey, 1989) . Virus replication in oropharyngeal epithelium accounts for spread of the virus between individuals, and latent infection of B lymphocytes establishes persistence. This persistent infection is controlled by immune mechanisms -particularly EBVspecific cytotoxic T cells (CTL). These can be detected in the also been used to study B cell infection in vivo. In the present study we have compared the results of these two biological assay systems with PCR detection of EBV DNA and a regression assay as a measure of host T cell immunity to EBV. PBMC from ten normal EBV-seropositive donors were studied and although each test gave consistent results on repeat assays, no correlation was found between any of the assays tested. This result suggests that each assay measures a separate aspect of EBV persistence in B cells, and indicates a previously unrecognized degree of heterogeneity in the B cell population in which EBV resides. circulation in all normal seropositive individuals and are directed against all the viral genes expressed in B cells immortalized by EBV in vitro [EB viral nuclear antigens (EBNA) 1, 2, 3a, 3b, 3c, leader protein (LP), latent membrane protein (LMP)-1, 2a, 2b] with the exception of EBNA1 (Murray et al., 1992) . However, the actual site of virus latency and the interrelationship between B cell and epithelial cell infection remains controversial. Most available evidence supports a model in which EBV establishes a non-productive infection in a pool of self-renewing B lymphocytes during primary infection which persists thereafter, despite CTL activity, by virtue of their restricted viral gene expression (Klein, 1994) .
One of the difficulties in studying in vivo EBV persistence is the very low level of circulating virus-infected B cells. Classically, a limiting dilution culture system has been used to quantify these cells (Lam et al., 1991 ; ; this measures the number of virus-infected cells in T cell-depleted peripheral blood mononuclear cells (PBMC) which give rise to spontaneous LCL. This technique estimates the level of EBVcarrying B cells in the circulation at 1 : 10& to 1:10' (Lam et al., 1991) . In this in vitro assay system, outgrowth of LCL can be suppressed by the viral DNA polymerase inhibitor acyclovir I. Johannessen and others I. Johannessen and others (Collins, 1983) , or by serum containing neutralizing antibody, indicating that they arise indirectly by release of virus from the in vivo EBV-carrying B cells and infection of bystanding normal B cells (Rickinson et al., 1977 ; Lewin et al., 1987) . Thus, only cells with the capacity to enter a productive cycle in culture are measured in this assay.
More recently, PCR analysis has been used to detect and quantify EBV DNA in PBMC when a value similar to that obtained in the culture assay has been calculated (Miyashita et al., 1995) . However, PCR detection of EBV DNA does not necessarily equate with biologically active virus.
Using the assays described above to monitor viral load, immunosuppressed patients such as transplant recipients can be shown to have raised numbers of virus-carrying cells in peripheral blood . This is a consequence of low or absent EBV-specific CTL activity, which is suppressed by drugs (Crawford et al., 1981) . Between 1 and 10 % of these patients develop EBV-associated B lymphoproliferative disease (BLPD) (Thomas et al., 1995) , but the relationship between the increased viral load and BLPD development remains obscure.
Recently, the severe combined immunodeficient (SCID) mouse, which lacks B and T cell immunity (Bosma et al., 1983) , has been used as a model for BLPD because it develops EBVassociated tumours after inoculation of PBMC from normal seropositive individuals (Mosier et al., 1988) . These tumours resemble LCL and BLPD in that they generally express all the latent viral gene products (Rowe et al., 1991) . However, whether the steps involved in their outgrowth mirror those in BLPD development remains unexplored.
Since it is not clear exactly which EBV-carrying B cell population each of these techniques detects, and whether they are directly comparable, we have used statistical analysis to compare the two biological assays, spontaneous outgrowth of LCL and tumour outgrowth in SCID mice, with semiquantitative PCR analysis in order to investigate the relationship between the three approaches to studying the nature of EBV infection in vivo and to monitoring viral load. Using PBMC from ten normal donors we found no correlation between these assays, and, additionally, no correlation with regression index as a measure of EBV-specific T cell-mediated immunity.
Methods
Blood donors and cell preparation. Peripheral blood was collected from ten healthy EBV-seropositive donors with their informed consent. PBMC were separated from heparinized blood by FicollHypaque (Pharmacia) gradient centrifugation and washed in wash medium (RPMI 1640 ; Gibco) containing 100 IU\ml penicillin, 100 µg\ml streptomycin, 2n7% (v\v) 7n5 % NaHCO $ , 2% (v\v) 1 M HEPES buffer and 2 % (v\v) foetal calf serum). The cells were either processed further for in vitro culture or resuspended in culture medium (RPMI 1640 containing 2 mM -glutamine, 100 IU\ml penicillin, 100 µg\ml streptomycin and 10 %, v\v, foetal calf serum) for intraperitoneal (i.p.) injection into SCID mice.
Spontaneous outgrowth of LCL. PBMC were depleted of T cells by E-rosetting using 5,2-aminoethylisothioronium bromide hydrobromide (AET ; Sigma)-treated sheep red blood cells. The E-negative cells were plated at 2i10& per well in round-bottom wells (Falcon) in culture medium (see above). Cultures were incubated at 37 mC in 5% CO # and fed weekly by replacement of half the medium. Plates were examined regularly and scored for wells containing actively growing, immortalized cells after 6 weeks.
Regression assay. EBV-specific CTL activity was assessed by in vitro regression assays following the standard method (Moss et al., 1978) . Briefly, PBMC obtained from peripheral blood were infected with concentrated B95-8 EBV, suspended in culture medium (see above) and seeded (200 µl per well) into five replicate wells of a 96-well flatbottomed microtitre plate (Sterilin) in serial doubling dilutions from 20i10& to 0n6i10& cells\ml. The cultures were fed weekly by replacement of half the medium, and after 4 weeks the wells were examined under an inverted microscope for features of regression. The strength of CTL activity was expressed as the regression index (RI), which was determined as the reciprocal of the lowest concentration of cells (i10& cells\ml) showing regression in three or more of the five wells multiplied by 100 (Whittle et al., 1984) .
Tumour outgrowth in SCID mice. CB-17 SCID mice were obtained from a breeding colony at the London School of Hygiene and Tropical Medicine under the supervision of G. J. Bancroft. Mice were maintained in microinsulator cages and fed autoclaved feed and water without antibiotics. Groups of three to five animals were injected i.p. with 4i10( to 10i10( unfractionated PBMC each mouse (Mosier et al., 1988) . Animals were culled either on showing signs of illness or after a previously determined time-limit of 100 days, and examined for macroscopic evidence of tumours which were harvested together with lung, liver and spleen. Tissue samples were snap-frozen in liquid nitrogen and fixed in neutral buffered formalin for histopathological and immunohistochemical studies.
PCR for EBV DNA detection. DNA was extracted from PBMC by routine methods (Sambrook et al., 1989) . To detect the presence of EBV DNA in samples, PCR was carried out using primer sets which amplify sequence of the EBV genome within the EBNA2 gene (Boyle et al., 1991) . The sensitivity of the primers was determined using Namalwa, an EBVpositive Burkitt's lymphoma (BL) cell line which is known to carry one or two integrated EBV genomes per cell (Henderson et al., 1983) . Tenfold dilutions of Namalwa cells (10', 10&, 10%, 10$, 10#, 10, 1) containing the corresponding number of EBV genomes were mixed with 10' cells of the EBV-negative BL cell line Ramos. Total DNA was extracted and subjected to PCR along with 1 µg of DNA from test samples. Sterile distilled water was always included in every PCR run as template-free negative control. PCR products (10 µl) were run on 2 % (w\v) agarose gel (Sigma) and Southern blotted onto nylon membranes (Amersham). The membranes were pre-hybridized for at least 2 h at 68 mC in hybridization solution (6i SSC, 5i Denhardt's solution, 0n5%, w\v, SDS and 100 µg denatured salmon sperm DNA). EBNA2-specific plasmid probes (50 ng ; Adldinger et al., 1985) were labelled with [α-$#P]dCTP (Amersham) by random priming, denatured by boiling and added to membranes. After overnight hybridization at 68 mC, the membranes were washed once in 2i SSC-0n1% (w\v) SDS at 68 mC for 30 min. The membranes were exposed to Hyper-MP films (Amersham) at k70 mC for 2 days. The autoradiographs were scanned through a gel scanner and the intensity of each positive PCR band measured. A standard curve was generated (see Fig. 1 a) . The test samples were compared with the control cell dilutions to obtain a semi-quantitative value of EBV genome copy number per sample. In vivo and in vitro parameters of EBV do not correlate In vivo and in vitro parameters of EBV do not correlate Histopathology and immunohistochemistry. Tissue sections of formalin-fixed material were routinely stained with haematoxylin and eosin (H&E) and tested by in situ hybridization for expression of EBVencoded RNAs (EBERs) (Howe & Steitz, 1986) . Frozen sections were routinely stained for EBNA expression by indirect anti-complement immunofluorescence using known positive and negative human sera (Reedman & Klein, 1973) .
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Results
Peripheral blood obtained from each of ten healthy, EBVseropositive volunteers on at least two occasions was tested for each of the four parameters of persistent EBV infection outlined above. The results are shown in Table 1 .
(1) Tumour outgrowth in SCID mice. Between 4i10( and 10i10( PBMC from each of the ten donors were injected i.p. into each of at least six SCID mice. PBMC from nine out of the ten (90 %) donors consistently gave rise to tumour outgrowth within a 100 day period, whereas PBMC from one donor (no. 4) consistently failed to grow. The incidence of tumour outgrowth in the mice was constant for each of the nine donors on at least two occasions but varied between donors from 13 to 90 %.
A representative selection of tumours was examined by H&E, EBNA and\or EBERs staining and all tumours were found to be EBV-positive B cell lymphomas.
(2) Spontaneous outgrowth. PBMC were depleted of E-rosettepositive T cells and plated at 2i10& cells per well on at least two separate occasions. E-negative cells from nine of the ten (90 %) donors gave spontaneous outgrowth of LCL, whereas cells from one donor (no. 2) failed to yield LCL. For the nine donors giving a positive result, the incidence of outgrowth ranged from 2 to 49 % of wells, and was similar for the same donors on different occasions.
(3) PCR detection of EBV DNA. PCR amplification of the EBNA2 gene sequence was carried out using 1 µg of test DNA from donor PBMC. The primers were sensitive enough to detect one copy of the EBV genome (from one Namalwa cell) in a mixture of 10' EBV-negative cells (Fig. 1 a, b) . EBV DNA was detected in PBMC from five out of ten (50 %) of the donors tested, and this was consistent on repeat testing of PBMC obtained on at least two different occasions (Fig. 1 b) . The autoradiographs were scanned in order to quantify the signal intensity of the bands. Comparison with the intensity of the signals given by the Namalwa dilutions gave an estimation of the viral load. The EBV DNA copy number in PBMC from those donors giving a positive signal varied from 2i10% to 100i10% per 10' PBMC. All donors were found to be carrying the type 1 strain of EBV. PCR analysis using EBV type 2-specific primers did not yield any positive results in any test samples (data not shown). To confirm the estimated EBV load in test samples obtained by densitometric comparison with Namalwa cells, experiments were carried out where DNA from a positive donor (no. 10) was serially 10-fold diluted in EBVnegative cells and PCR was carried out. The genome copy number was estimated to be 10' in 10' PBMC, which was in agreement with our findings (Table 1 ). In spite of spontaneous in vitro outgrowth of an LCL from PBMC from donor no. 8, EBV DNA was not detected in the donor's peripheral blood.
I. Johannessen and others I. Johannessen and others (a) ( b ) Fig. 1 . (a) Standard curve obtained using the EBV-positive cell line Namalwa. Serial 10-fold dilutions of Namalwa cells were mixed with a 10 6 EBV-negative Ramos cells, DNA extracted and PCR carried out with EBNA2 primers. The PCR products were run on 2 % agarose gel, transferred to nylon membrane and hybridized with 32 P-labelled EBNA2-specific plasmid probe. The autoradiograph was scanned through a densitometer, the volume of each band measured (i10 3 ; y-axis) and a standard curve was generated. The scale on the x-axis from 1 to 7 denotes 10 Regression assay † 1 3 6 4 2 n 5 2 8 2 1 2 n 5 3 3 5 2 2 n 5 4 3 1 8 8 5 9 9 7 5 n 5 6 3 3 n 5 5 8 7 6 3 n 5 3 8 8 3 8 1 0 1 0 9 7 7 9 2 n 5 10 10 10 6 5n5 * Spearman's rank correlation : lowest value given lowest rank, highest value given highest rank. † Regression assay ranked according to the cell concentration giving rise to a regression index (RI). Analysis of the data when using the ranked values of RI gave similar results.
To determine whether the endogenous EBV isolate of this particular donor could be amplified by PCR, DNA was extracted from the LCL cells and EBNA2 PCR was carried out. Our PCR system was capable of detecting the endogenous virus thus indicating that the negative EBNA2 PCR results for PBMC from donor no. 8 were due to the presence of less than one genome copy per 10' cells and not due to the inability to detect the particular isolate.
(4) Regression analysis. Donor PBMC were infected with EBV in vitro and cultured in doubling dilutions from 20i10& to 0n6i10& cells\ml in five replicate wells. Cultures were scored for regression\outgrowth after 4 weeks of culture. Cells from all ten donors showed regression, giving a regression index of either 10 (donor 8), 20 (donors 4, 6, 7), 27 (donors 5, 10) or 40 (donors 1, 2, 3, 9).
(5) Statistical analysis. Spearman's rank correlation was used to compare the four sets of results with each other. The ranking is shown in Table 2 . Values for each of the variables were ranked separately in ascending order of magnitude and Spearman's rank correlation (denoted by r s ) was calculated. Overall, the value of r s was between k0n13 and 0n49.
Comparing r s on each occasion with critical values showed little or no relationship between any of the ranks (all P-values 0n1).
Discussion
This study used statistical analysis to compare four different assays which are regularly used as research tools to study EBV persistence and immunity in the normal and immunocompromised hosts. All ten donors gave positive results in at least one assay indicating that each was persistently infected with EBV. However, although each assay gave consistent In vivo and in vitro parameters of EBV do not correlate In vivo and in vitro parameters of EBV do not correlate results when repeated on PBMC from the same donor taken at different time-points, when the results of the different assays were compared no correlation was found. This is a surprising result which suggests that each assay measures a different parameter of virus persistence in vivo.
The PCR assay detected EBV DNA in 50 % of donors tested, and this included the one donor whose PBMC did not give spontaneous outgrowth in culture. This value is in line with PCR results from other laboratories (Gopal et al., 1990) . PCR is not a biological assay and it is therefore expected to detect all the EBV DNA present in the samples whether infectious or non-infectious. In addition, the primers used in this study were designed to amplify a region of the EBV genome in the EBNA2 gene, which is present and amplifiable in both type 1 and type 2 isolates (although all donors were subsequently found only to carry type 1 virus). Since all donors demonstrated evidence of EBV carriage in B cells in at least one of the other assays, the negative PCR results in 50 % of the donors tested must be due to the level of EBV DNA being below the sensitivity of the assay. The PCR method used was shown to be sensitive enough to detect the one to two genome copies present in one Namalwa cell in a background of 10' EBV-negative cells, and therefore EBV DNA in the 50 % of donors who gave negative results must have been at a level below one genome per 10' PBMC. The results could not have arisen due to an inability of the PCR to detect endogenous virus since we successfully amplified the virus in a spontaneous LCL from one donor tested (no. 8) whose PBMC gave negative PCR results.
The two biological assays, that is spontaneous LCL outgrowth in vitro and tumour outgrowth in vivo in SCID mice, both gave positive results with PBMC from 90 % of donors ; these levels of detection are consistent with other published results (Picchio et al., 1992) . However, in each case PBMC from one donor consistently gave negative results, but these were different donors in each assay. Since both these donors were found to have type 1 EBV isolates by PCR, the lack of outgrowth could not be attributed to the less vigorous in vitro growth promotion properties of type 2 isolates (Rickinson et al., 1987) . The lack of correlation between the two assays probably reflects the quite distinct mechanisms of outgrowth of B cells in the in vivo and in vitro systems. Early studies using spontaneous in vitro outgrowth from T cell-depleted PBMC populations from normal donors show that this is predominantly a two-step process where virus-carrying cells undergo lytic infection early in the culture period and the virus released infects and immortalizes co-cultured normal B cells (Rickinson et al., 1977) . This process is inhibited by the drug acyclovir, which blocks lytic reactivation (Collins, 1983) , and by neutralizing antibody, which prevents secondary infection ; only very rarely have B cells capable of direct outgrowth in culture been detected (Lewin et al., 1987) . Outgrowth of LCL is also prevented by co-cultured, autologous T cells which contain an EBV-specific cytotoxic population (Moss et al., 1978) and these cells are therefore removed or inactivated prior to culture. Both LCL and tumours arising in SCID mice inoculated with seropositive PBMC exhibit a similar phenotype (Rowe et al., 1991) . However, in contrast to LCL, tumour outgrowth in SCID mice is not blocked by acyclovir (Boyle et al., 1992) . The presence of CD4 + or CD8 + T cells in the inoculum is an absolute requirement for their growth (Veronese et al., 1992 ; I. Johannessen, unpublished results) , suggesting that SCID tumours arise from a subpopulation of EBV-carrying B cells which have the capacity for direct outgrowth in vivo if supplied with T cell-derived soluble factors and which are quite distinct from the EBV-carrying cells which give rise to spontaneous LCL. The present study lends support to this suggestion and further suggests that tumour production in SCID mice is a valid in vivo model for BLPD. BLPD tumours often contain a large infiltrate of non-malignant CD4 + T cells which may act as a ' feeder ' population, supplying essential soluble factors to initiate and maintain tumour growth (Perera et al., 1998) .
Since the two biological assays tested here show no correlation and are clearly testing very different aspects of EBV persistence, the lack of their correlation with levels of EBV DNA measured by semi-quantitative PCR, although contrasting with a published report (Miyashita et al., 1995) , is not unexpected. It confirms the suspicion that not all EBV DNAcarrying cells have the ability to release virus in culture or undergo direct proliferation in a SCID mouse. An alternative explanation for these results would be that the biological assays are inherently variable, giving inconsistent results which make any comparison invalid. However, this is not the case in this study since each assay was repeated on at least two different occasions and found to give consistent results.
The final statistical analysis showed no correlation between levels of EBV-specific CTL-activity as measured by a regression assay, and any of the assays for B cell infection used. This suggests that the T cells are not directly controlling the level of B cell infection in the circulation, and supports the suggestion that many of the EBV-carrying B cells are invisible to T cell immunosurveillance because of their restricted viral gene expression (Klein, 1994) . The high level of EBV-specific cytotoxic T cells which is maintained in the peripheral blood of seropositive donors may therefore be targeting B cells in lymph nodes, tissues or epithelial sites which are possibly at a different stage of activation\differentiation and capable of expressing all the latent viral genes known to be recognized by these T cells (Murray et al., 1992) .
The data presented here indicate a degree of heterogeneity in the EBV-carrying B cell population in the peripheral blood of normal individuals and clarify the role of individual assay systems in the study of EBV persistence in the normal and immunocompromised host.
